Sharma Mokshya, Ahmed Aijaz, Wong Robert J
1 Division of Gastroenterology and Hepatology, Alameda Health System, Highland Hospital, Oakland, CA, USA.
2 Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
Prog Transplant. 2017 Sep;27(3):225-231. doi: 10.1177/1526924817715468. Epub 2017 Jul 4.
The age of liver transplantation recipients in the United States is steadily increasing. However, the impact of age on liver transplant outcomes has demonstrated contradictory results.
We aim to evaluate the impact of age on survival following liver transplantation among US adults.
Using data from the United Network for Organ Sharing registry, we retrospectively evaluated all adults undergoing liver transplantation from 2002 to 2012 stratified by age (aged 70 years and older vs aged <70 years), presence of hepatocellular carcinoma, and hepatitis C virus status. Overall survival was evaluated with Kaplan-Meier methods and multivariate Cox proportional hazards models.
Compared to patients aged <70 years, those aged 70 years and older had significantly lower 5-year survival following transplantation among all groups analyzed (hepatocellular carcinoma: 59.9% vs 68.6%, P < .01; nonhepatocellular carcinoma: 61.2% vs 74.2%, P < .001; hepatitis C: 60.7% vs 69.0%, P < .01; nonhepatitis C: 62.6% vs 78.5%, P < .001). On multivariate regression, patients aged 70 years and older at time of transplantation was associated with significantly higher mortality compared to those aged <70 years (hazards ratio: 1.67; 95% confidence interval: 1.48-1.87; P < .001).
The age at the time of liver transplantation has continued to increase in the United States. However, patients aged 70 years and older had significantly higher mortality following liver transplantation. These observations are especially important given the aging cohort of patients with chronic liver disease in the United States.
美国肝移植受者的年龄在稳步上升。然而,年龄对肝移植结果的影响呈现出相互矛盾的结果。
我们旨在评估年龄对美国成年人肝移植术后生存的影响。
利用器官共享联合网络登记处的数据,我们对2002年至2012年接受肝移植的所有成年人进行了回顾性评估,根据年龄(70岁及以上与小于70岁)、肝细胞癌的存在情况以及丙型肝炎病毒状态进行分层。采用Kaplan-Meier方法和多变量Cox比例风险模型评估总生存率。
与小于70岁的患者相比,在所有分析组中,70岁及以上的患者移植后的5年生存率显著较低(肝细胞癌:59.9%对68.6%,P<.01;非肝细胞癌:61.2%对74.2%,P<.001;丙型肝炎:60.7%对69.0%,P<.01;非丙型肝炎:62.6%对78.5%,P<.001)。在多变量回归分析中,移植时年龄在70岁及以上的患者与小于70岁的患者相比,死亡率显著更高(风险比:1.67;95%置信区间:1.48 - 1.87;P<.001)。
在美国,肝移植时的年龄持续上升。然而,70岁及以上的患者肝移植后的死亡率显著更高。鉴于美国慢性肝病患者群体的老龄化,这些观察结果尤为重要。